Page last updated: 2024-12-05

trifluoromethylphenothiazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID7082
CHEMBL ID541018
CHEBI ID92925
SCHEMBL ID560225
MeSH IDM0063691

Synonyms (51)

Synonym
AC-1827
c13h8f3ns
2-trifluoromethylphenothiazine
92-30-8
phenothiazine, 2-(trifluoromethyl)-
2-(trifluoromethyl)phenothiazine
nsc50438
trifluoromethylphenothiazine
10h-phenothiazine, 2-(trifluoromethyl)-
nsc-50438
einecs 202-145-7
nsc 50438
2-(trifluoromethyl)-10h-phenothiazine
brn 0226580
SR-01000441858-2 ,
T-6400
STK325860
CHEMBL541018
T1407
AKOS001305498
2-(triflouomethyl) phenothiazine
2-trifluoromethyl-phenothiazine
2-trifluoromethyl phenothiazine
MLS003166902
smr001814476
CCG-44949
2-trifluoromethyl-10h-phenothiazine
unii-877s053kx3
877s053kx3 ,
4-27-00-01352 (beilstein handbook reference)
FT-0608971
2-(trifluoromethyl)-phenothiazine
SCHEMBL560225
DTXSID3059050
cid_7082
bdbm65841
2-(trifluoromethyl)-10h-phenothiazine #
trifluoromethyl)-10h-phenothiazine, 2-(
mfcd00005018
SR-01000441858-1
sr-01000441858
CHEBI:92925
CS-W021465
Q27164667
SY049028
AS-14298
BRD-K53032901-001-03-8
AMY32660
O10543
EN300-20475
Z104478346
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenothiazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NADPH oxidase 1Homo sapiens (human)IC50 (µMol)5.60400.04401.26095.5000AID2532; AID2556; AID434997; AID435002; AID435009
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1161116Antimicrobial activity against Mycobacterium smegmatis (MC2) 155 after 24 hrs by serial macrobroth dilution method2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Incorporation of triphenylphosphonium functionality improves the inhibitory properties of phenothiazine derivatives in Mycobacterium tuberculosis.
AID420787Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors.
AID1161117Antimicrobial activity against Mycobacterium tuberculosis H37Ra after 5 days by serial macrobroth dilution method2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Incorporation of triphenylphosphonium functionality improves the inhibitory properties of phenothiazine derivatives in Mycobacterium tuberculosis.
AID1727546Inhibition of erastin-induced ferroptosis in human HT-1080 cells assessed as cell viability incubated for 48 hrs by MTT assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Structure-activity relationship studies of phenothiazine derivatives as a new class of ferroptosis inhibitors together with the therapeutic effect in an ischemic stroke model.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's2 (28.57)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.78 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]